Mesophasic proliposomat system for levonorgestrel was developed and evaluated both in vitro and in vivo. The vesicles were mostly unilamellar, however, few vesicles were multilamellar which budded off spontaneously upon hydration. The release of drug from this system adhered to zero order kinetics. The effect of alcohols and volatile oils on transdermal flux was investigated. The flux was found to be the highest for alcohol, and followed by that for lemon oil. The in vivo studies indicate the requirement for a loading dose, since, a significant lag phase was observed before the therapeutic levels were reached. This system was, however, superior to the PEG-based ointment system which was employed as the control formulation. The results demonstrate the potential of proliposomal system for efficaceous transdermal delivery of hydrophobic drugs.
1. Egbaria, K. and N. Weiner. 1991. "Liposomes as a Topical Drug Delivery System Evaluated by In vitro Diffusion Studies," in Cosmetic and Pharmaceutical Applications of Polymers, C. G. Gebelein, ed., New York: Plenum Press, pp. 215-224.
2.
2. Blume, A., M. Jansen, M. Ghyezy and J. Gareiss. 1993. "Interaction of Phospholipid Liposomes with Lipid Model Mixtures for Stratum Corneum Lipids,"Int. J. Pharm., 99:219-228.
3.
3. Junginger, H. E., H. E. J. Hofland and J. A. Bouwstra. 1991. "Liposomes and Niosomes: Interaction with Human Skin,"Cosmet. Toil., 106:48-50.
4.
4. Lash, J., R. Laub and W. Wohlrab. 1992. "How Deep Do Intact Liposomes Penetrate into Human Skin"?J. Controlled Release, 18:55-58.
5.
5. Knepp, V. M., R. S. Hinz, Szoka, F. C., Jr. and R. H. Guy. 1988. "Controlled Drug Release from a Novel Liposomat Drug Delivery System I: Transdermal Delivery Characteristics,"J. Controlled Release, 5:211-221.
6.
6. Knepp, V. M., Szoka, F. C., Jr. and R. R. Cuy. 1990. "Controlled Drug Release from a Novel Liposomat Drug Delivery System II: Transdermal Delivery Characteristics,"J. Controlled Release, 12:25-30.
7.
7. Junginger, H. E., H. E. J. Hofland and J. A. Bouwstra. 1991. "Liposomes and Nisomes: Interaction with Human Skin,"Cosm. & Toil, 106(8):45-50.
8.
8. Payne, N. I., P. Timmins, C. V. Ambrose, M. D. Ward and ?.?. Ridgway. 1986. "Proliposomes: A Novel Solution to an Old Problem,"J. Pharm, Sci., 75(4):325-329.
9.
9. Payne, N. I., I. Browning and C. A. Hynes. 1986. "Characterisation of Proliposomes,"J. Pharyn. Sci., 75(4):330-333.
10.
10. Katare, O. P., S. P. Vyas and V. K. Dixit. 1990. "Efferceseent Granules Based Proliposomes of Ibuprofen,"J. Microencapsulation, 7(4):455-462.
11.
11. Katare, O. B., S. P. Vyas and V. K. Dixit. 1991. "Proliposomes of Indomethacin for Oral Administration,"J. Microencapsulation, 8(i):1-7.
12.
12. Alini, B. N., S. K. Kim and C. K. Shim. 1995. "Proliposomes as an Intransal Dosage Form for Sustained Delivery of Propranolol,"J. Controlled Release, 34:203-210.
13.
13. Supersaxo, K., W. R. Hein and H. Steffen. 1991. "As a Proliposomal Lymphotropic Drug Carriers,"1286-1291.
14.
14. Onyuksel, A. H. and K. Son. 1992. "Mixed Micelles as Proliposomes for Solubilization of Teniposides,"Pharm. Res., 9:1556-1562.
15.
15. Perrett, S., M. Golding and P. Williams. 1991. "A Simple Method of Preparation of the Liposomes for Pharmaceutical Application; Characterisation of Liposomes,"J. Pharm. Pharmacol., 43:154-161.
16.
16. Sant, V P, M. R. Deo, A. J. Khopade, S. R. Parakh and S. G. Deshpande. 1996. "Iontophoretically Facilitated Transdermal Delivery of Salbutamol Sulphate,"Indian Drugs, 33(s):202-207.
17.
17. Friend, D., P. Catz, J. Heller, J. Reid and J. Baker. 1988. "Transdermal Delivery of Levonorgestrel I: Alkanols as Permeation Enhancers in vitro,"J. Controlled Release, 7:243-250.
18.
18. Valia, K. H., Y. W. Chien and E. C. Shinai. 1984. "Long Term Permeation Kinetics of Estradiol I-Effect of Drug Solubilizer PEG 40G,"Drug Rev. Ind. Pharm., 10:95t-98l.
19.
19. Pleiss du, J., C. Ramachandran, N. Weiner and D. G. Muller. 1994. "The Influence of Particle Size of Liposomes on the Deposition of Drug into Skin,"Int. J. Pharm., 103:277-282.
20.
20. Hofland, H. E. J., J. A. Bouwstra, R. Spies, H. E. Bodde, C. Cullander and H. E. Junginger. 1992. "Transdermal Delivery of Estradiol by Niosomes in-Vitro,"Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 19:230-231.
21.
21. Hofland, H. E. J., J. A. Bouwstra, H. E. Bodde, F. Spies, R. Van der Geest and H. E. Junginger. 1991. "Transdermal Delivery of Estradiol from Nonionic Surfactant Vesicles and Visualization of Effects These Vesicles Have on Human Skin in Vitro,"Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 18:307-308.
22.
22. Ishii, F., A. Takamura and Y. Ishigami. 1995. "Procedure for Preparation of Lipid Vesicles (Liposomes) Using the Coacervation (Phase Separation) Technique,"Langmuir, 1:483-486.
23.
23. Knutson, K., S. L. Krill and J. Zhang. 1990. "Solvent Mediated Alterations of the Stratum Corneum,"J. Controlled Release, II:93-103.
24.
24. Catz, P. and D. R. Friend. 1990. "Transdermal Delivery of Levonorgestrel VIII Effect of Enhancers on Rat Skin, Hairless Guniea Pig Skin and Human Skin,"Int. J. Pharm., 53:93-102.
25.
25. Micliniak, B. and J. Chapman. 1993. "Transdermal Delivery of Indomethacin and Levonorgestrel using Clofibrid Acid Amides as Penetration Enhancers,"Drug Delivery, 1:35-41.
26.
26. Friend, D., P. Catz and J. Heller. 1989. "Simple Alkyl Esters as Skin Permeation Enhancers,"J. Controlled Release, 9:33-41.
27.
27. Chen, G. S., D. D. Kim and Y. W. Chien. 1995. "Dual Controlled Transdermal Delivery of Enhanced Levonorgestrel and Estradiol: Enhanced Permeation-and Modulated Delivery,"J. Controlled Release, 34:129-143.
28.
28. Nagai, T., M. Sato and K. Takayama. 1994. "Liposomes for Mechanistic Study of Percutaneous Absorption Promoters such as Terpenes," in E. Touitou, H. E. Jtinginger, N. D. Weiner, T. Nagai and M. Mezei (eds.), J. Pharm. Sci.,83(9):1189-1203.
29.
29. William, A. C. and B. W. Barry. 1991. "Terpenes and the Lipid Protein Partition Theory of Skin Penetration Enhancement,"Pharm. Res., 8:17-24.
